



Press release

## **SHL announces invitation to Special General Meeting**

**Tel Aviv / Zurich, 22 November 2016** – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that a Special General Meeting of the Shareholders will be held on January 5, 2017 at 13:00 p.m. (Israel Time), at the Company’s registered office, located at 90 Yigal Alon Street, Ashdar Building, Tel-Aviv, Israel. The agenda shall include the following matters:

1. Election of one (1) Independent (External) Director to the Board of Directors for a three (3) year term. The current candidates are: Mr. Ronen Harel and Mr. Gil Sharon.  
The new Independent Director will replace Nehama Ronen, serving on SHL’s Board as an Independent Director since 2007, whose term under Israeli law has ended this year and cannot be extended.  
The vote with respect to each of the above shall be conducted separately. Pursuant to the Company’s Articles of Association, in the event that the number of candidates who receive the requisite majority votes exceeds the number of vacancies, then the candidate who receives the higher number of votes shall be so elected, and to the extent two (2) or more of said candidates receive an equal number of votes, then a second vote shall be conducted solely with respect to such candidates. The Independent (external) director nominees have submitted to the Company the declarations required pursuant to Sections 224b, 241(a) of the Israeli Companies Law of 1999 (the “Companies Law”) with respect to fulfilling the legal requirements to serve as an Independent (external) Director of the Company.
2. Following recommendation and approval by the Company’s Compensation Committee and Board - Approval of Option Grant of 18,000 Options to the newly elected Independent (external) Director.
3. Following recommendation and approval by the Company’s Compensation Committee and Board - Approval of Option Grants of 18,000 Options to each “Other” Director as such term is defined under applicable law.
4. Following recommendation and approval by the Company’s Compensation Committee and Board - Approval of Option Grants of 50,000 Options to the Chairman of the Board, Mr. Uzi Blumensohn.
5. Following recommendation and approval by the Company’s Compensation Committee and Board - Approval of Updated Terms of Engagement Mr. Yoav Rubinstein, the Company’s Senior Vice President, Head of Global Business Development (via his wholly owned company).

The company has decided to discontinue publishing the invitation to shareholder meetings in newspapers. The full invitation to the SGM (including CVs of candidates, proposed resolutions, ballot and proxy forms) can be downloaded on <http://www.shl-telemedicine.com/about-us/investorrelations/general-meeting/>

### **For further information, please contact:**

Martin Meier-Pfister, IRF Communications, phone: +41 43 244 81 40, [shl@irfcom.ch](mailto:shl@irfcom.ch)

### **About SHL Telemedicine**

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the



healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit the web site at [www.shl-telemedicine.com](http://www.shl-telemedicine.com).

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.